169 related articles for article (PubMed ID: 2081278)
1. [Treatment of metastatic melanoma with dacarbazine recombinant interferon alfa 2A combination: results of multicentric study].
Avril MF; Beerblock K; Dreno B; Delaunay M; Bonerandi JJ; Guillaume JC; Souteyrand P; Kalis B; Chevrant-Breton J; Verret J
Bull Cancer; 1990; 77(12):1183-91. PubMed ID: 2081278
[TBL] [Abstract][Full Text] [Related]
2. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial.
Thomson DB; Adena M; McLeod GR; Hersey P; Gill PG; Coates AS; Olver IN; Kefford RF; Lowenthal RM; Beadle GF
Melanoma Res; 1993 Apr; 3(2):133-8. PubMed ID: 8518552
[TBL] [Abstract][Full Text] [Related]
4. Immunochemotherapy with recombinant interferon-alpha 2b plus dacarbazine in the treatment of advanced malignant melanoma.
Strojan P; Rudolf Z
Melanoma Res; 1997 Oct; 7(5):420-7. PubMed ID: 9429226
[TBL] [Abstract][Full Text] [Related]
5. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma.
Pyrhönen S; Hahka-Kemppinen M; Muhonen T
J Clin Oncol; 1992 Dec; 10(12):1919-26. PubMed ID: 1280673
[TBL] [Abstract][Full Text] [Related]
6. [Combination of dacarbazine, cisplatin and interferon alpha in the treatment of metastatic melanoma].
Tessier MH; Mansat E; Legoux B; Litoux P; Dreno B
Ann Dermatol Venereol; 1996; 123(9):538-42. PubMed ID: 9615103
[TBL] [Abstract][Full Text] [Related]
7. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
Bajetta E; Di Leo A; Zampino MG; Sertoli MR; Comella G; Barduagni M; Giannotti B; Queirolo P; Tribbia G; Bernengo MG
J Clin Oncol; 1994 Apr; 12(4):806-11. PubMed ID: 8151323
[TBL] [Abstract][Full Text] [Related]
8. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
Legha SS; Ring S; Eton O; Bedikian A; Buzaid AC; Plager C; Papadopoulos N
J Clin Oncol; 1998 May; 16(5):1752-9. PubMed ID: 9586888
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: long-term follow-up of two phase II studies.
Hersey P; McLeod GR; Thomson DB
Br J Haematol; 1991 Oct; 79 Suppl 1():60-6. PubMed ID: 1931712
[TBL] [Abstract][Full Text] [Related]
10. Dacarbazine and interferon-alpha 2a in advanced malignant melanoma: high response rate and prolongation of response duration occur in different patient subpopulations.
Betticher DC; Lee SM; Morris C; Clemons M; Thatcher N
Melanoma Res; 1995 Aug; 5(4):277-82. PubMed ID: 7496165
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma.
Bajetta E; Negretti E; Giannotti B; Brogelli L; Brunetti I; Sertoli MR; Bernengo MG; Sofra MC; Maifredi G; Zumiani G
Am J Clin Oncol; 1990 Oct; 13(5):405-9. PubMed ID: 2220660
[TBL] [Abstract][Full Text] [Related]
12. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of metastatic melanoma treated with a combination of interferon alfa 2b, dacarbazine and nimustine.
Gröhn P; Kumpulainen E; Nuortio L; Hakala T; Vuoristo MS; Korpela M; Heikkinen M; Salmi R; Jakobsson M; Numminen S
Eur J Cancer; 1992; 28(2-3):441-3. PubMed ID: 1591060
[TBL] [Abstract][Full Text] [Related]
14. Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program.
Stark JJ; Dillman RO; Schulof R; Wiemann MC; Barth NM; Honeycutt PJ; Soori G
Cancer; 1998 May; 82(9):1677-81. PubMed ID: 9576288
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
Hauschild A; Dummer R; Ugurel S; Kaehler KC; Egberts F; Fink W; Both-Skalsky J; Laetsch B; Schadendorf D
Cancer; 2008 Sep; 113(6):1404-11. PubMed ID: 18615619
[TBL] [Abstract][Full Text] [Related]
16. Dacarbazine and interferon alpha for stage IV malignant melanoma.
Tamm I; Grimme H; Bergen E; Simon JC; Schöpf E; Mertelsmann R; Lindemann A; Brennscheidt U
Oncology; 1997; 54(4):270-4. PubMed ID: 9216849
[TBL] [Abstract][Full Text] [Related]
17. [Combination of dacarbazine, vindesine and interferon alpha in the treatment of metastatic melanoma].
Mansat-Krzyzanowska E; Dreno B
Ann Dermatol Venereol; 1994; 121(12):884-7. PubMed ID: 7632005
[TBL] [Abstract][Full Text] [Related]
18. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
Thompson JA; Gold PJ; Markowitz DR; Byrd DR; Lindgren CG; Fefer A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S29-34. PubMed ID: 9457390
[TBL] [Abstract][Full Text] [Related]
19. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study.
Stoter G; Shiloni E; Aamdal S; Cleton FJ; Iacobelli S; Bijman JT; Palmer P; Franks CR; Rodenhuis S
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S41-3. PubMed ID: 2697578
[TBL] [Abstract][Full Text] [Related]
20. A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study.
Sondak VK; Liu PY; Flaherty LE; Fletcher WS; Periman P; Gandara DR; Taylor SA; Balcerzak SP; Meyskens FL
Cancer J Sci Am; 1999; 5(1):41-7. PubMed ID: 10188060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
